IL-23 |
|
|
|
|
|
|
|
Risankizumab |
Anti-IL-23 |
Induction dose: 150 mg weeks 0 and 4/SC |
Moderate to severe plaque psoriasis (>10% PASI, BSA or DLQI) |
74% PASI 90 week 122525 Strober B, Thaçi D, Sofen H, Kircik L, Gordon KB, Foley P, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 POETYK PSO-2 trial. J Am Acad Dermatol. 2023;88:29-39.,2626 Xie X, Wang Y, Yao S, Xia Y, Luo H, Li L, et al. Biologics recommendations for patients with psoriasis: a critical appraisal of clinical practice guidelines for psoriasis. J Dermatol Treat. 2022;33:2038-50.
|
Yes |
I |
A |
Maintenance dose: 150 mg every 12 weeks/SC |
Guselkumab |
Anti-IL-23 |
Induction dose: 100 mg weeks 0 and 4/SC |
Moderate to severe plaque psoriasis (>10% PASI, BSA or DLQI) |
68% PASI 90 week 122525 Strober B, Thaçi D, Sofen H, Kircik L, Gordon KB, Foley P, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 POETYK PSO-2 trial. J Am Acad Dermatol. 2023;88:29-39.,2626 Xie X, Wang Y, Yao S, Xia Y, Luo H, Li L, et al. Biologics recommendations for patients with psoriasis: a critical appraisal of clinical practice guidelines for psoriasis. J Dermatol Treat. 2022;33:2038-50.
|
Yes |
I |
A |
Maintenance dose: 100 mg every 8 weeks/SC |
Tildrakizumab |
Anti-IL-23 |
Induction dose: 100 mg weeks 0 and 4/SC |
Moderate to severe plaque psoriasis (>10% PASI, BSA or DLQI) |
39% PASI 90 week 122525 Strober B, Thaçi D, Sofen H, Kircik L, Gordon KB, Foley P, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 POETYK PSO-2 trial. J Am Acad Dermatol. 2023;88:29-39.,2626 Xie X, Wang Y, Yao S, Xia Y, Luo H, Li L, et al. Biologics recommendations for patients with psoriasis: a critical appraisal of clinical practice guidelines for psoriasis. J Dermatol Treat. 2022;33:2038-50.
|
Yes |
I |
A |
Maintenance dose: 100 mg every 12 weeks/SC |
IL-17 |
|
|
|
|
|
|
|
Brodalumab |
Anti-IL-17 |
Induction dose: 210 mg weeks 0, 1 and 2/SC |
Moderate to severe plaque psoriasis (>10% PASI, BSA or DLQI) |
73% PASI 90 week 122525 Strober B, Thaçi D, Sofen H, Kircik L, Gordon KB, Foley P, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 POETYK PSO-2 trial. J Am Acad Dermatol. 2023;88:29-39.,2626 Xie X, Wang Y, Yao S, Xia Y, Luo H, Li L, et al. Biologics recommendations for patients with psoriasis: a critical appraisal of clinical practice guidelines for psoriasis. J Dermatol Treat. 2022;33:2038-50.
|
Yes |
I |
A |
Maintenance dose: 210 mg every 2 weeks/SC |
Ixekizumab |
Anti-IL-17 |
Induction dose: 160 mg week 0 SC, 80 mg weeks 2, 4, 6, 8, 10, 12/SC |
Moderate to severe plaque psoriasis (>10% PASI, BSA or DLQI) |
72% PASI 90 week 122525 Strober B, Thaçi D, Sofen H, Kircik L, Gordon KB, Foley P, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 POETYK PSO-2 trial. J Am Acad Dermatol. 2023;88:29-39.,2626 Xie X, Wang Y, Yao S, Xia Y, Luo H, Li L, et al. Biologics recommendations for patients with psoriasis: a critical appraisal of clinical practice guidelines for psoriasis. J Dermatol Treat. 2022;33:2038-50.
|
Yes |
I |
A |
Maintenance dose: 80 mg every 4 weeks/SC |
Secukinumab |
Anti-IL-17 |
Induction dose: 300 mg weeks 0,1,2,3 and 4/SC |
Moderate to severe plaque psoriasis (>10% PASI, BSA or DLQI) |
60% PASI 90 week 122525 Strober B, Thaçi D, Sofen H, Kircik L, Gordon KB, Foley P, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 POETYK PSO-2 trial. J Am Acad Dermatol. 2023;88:29-39.,2626 Xie X, Wang Y, Yao S, Xia Y, Luo H, Li L, et al. Biologics recommendations for patients with psoriasis: a critical appraisal of clinical practice guidelines for psoriasis. J Dermatol Treat. 2022;33:2038-50.
|
Yes |
I |
A |
Maintenance dose: 300 mg every month/SC |
IL-12/23 |
|
|
|
|
|
|
|
Ustekinumab |
Anti-IL-12/23 |
Induction dose: <100 kg: 45 mg weeks 0 and 4/SC; >100 kg: 90 mg weeks 0 and 4/SC |
Moderate to severe plaque psoriasis (>10% PASI, BSA or DLQI) |
Adults: 42% PASI 90 week 122525 Strober B, Thaçi D, Sofen H, Kircik L, Gordon KB, Foley P, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 POETYK PSO-2 trial. J Am Acad Dermatol. 2023;88:29-39.,2626 Xie X, Wang Y, Yao S, Xia Y, Luo H, Li L, et al. Biologics recommendations for patients with psoriasis: a critical appraisal of clinical practice guidelines for psoriasis. J Dermatol Treat. 2022;33:2038-50.
|
Yes |
I |
A |
Maintenance dose: <100 kg: 45 mg weeks every 12-weeks/SC; >100 kg: 90 mg every 12-weeks/SC |
TNF-a |
|
|
|
|
|
|
|
Infliximab |
Anti-TNF-α |
Induction dose: 5 mg/kg weeks 0, 2 and 6/IV |
Moderate to severe plaque psoriasis (>10% PASI, BSA or DLQI) |
53% PASI 90 week 122525 Strober B, Thaçi D, Sofen H, Kircik L, Gordon KB, Foley P, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 POETYK PSO-2 trial. J Am Acad Dermatol. 2023;88:29-39.,2626 Xie X, Wang Y, Yao S, Xia Y, Luo H, Li L, et al. Biologics recommendations for patients with psoriasis: a critical appraisal of clinical practice guidelines for psoriasis. J Dermatol Treat. 2022;33:2038-50.
|
Yes |
I |
A |
Maintenance dose: 5 mg/kg every 8 weeks/IV |
Adalimumab |
Anti-TNF-α |
Induction dose: 80 mg week 0, 40 mg week 1/SC |
Moderate to severe plaque psoriasis (>10% PASI, BSA or DLQI) |
41% PASI 90 week 122525 Strober B, Thaçi D, Sofen H, Kircik L, Gordon KB, Foley P, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 POETYK PSO-2 trial. J Am Acad Dermatol. 2023;88:29-39.,2626 Xie X, Wang Y, Yao S, Xia Y, Luo H, Li L, et al. Biologics recommendations for patients with psoriasis: a critical appraisal of clinical practice guidelines for psoriasis. J Dermatol Treat. 2022;33:2038-50.
|
Yes |
I |
A |
Maintenance dose: 40 mg every 2 weeks/SC |
Certolizumab |
Anti-TNF-α |
Induction dose: 400 mg weeks 0, 2 and 4/SC |
Moderate to severe plaque psoriasis (>10% PASI, BSA or DLQI) |
40% PASI 90 week 122525 Strober B, Thaçi D, Sofen H, Kircik L, Gordon KB, Foley P, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 POETYK PSO-2 trial. J Am Acad Dermatol. 2023;88:29-39.,2626 Xie X, Wang Y, Yao S, Xia Y, Luo H, Li L, et al. Biologics recommendations for patients with psoriasis: a critical appraisal of clinical practice guidelines for psoriasis. J Dermatol Treat. 2022;33:2038-50.
|
Yes |
I |
A |
Maintenance dose: <90 kg: 200 mg every 2-weeks/SC; >90 kg: 400 mg every 2-weeks/SC |
Golimumab |
Anti-TNF-α |
Induction dose:200 mg week 0, 100 mg week 2 |
Moderate to severe plaque psoriasis (>10% PASI, BSA or DLQI) |
40% PASI 75 in week 142525 Strober B, Thaçi D, Sofen H, Kircik L, Gordon KB, Foley P, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 POETYK PSO-2 trial. J Am Acad Dermatol. 2023;88:29-39.
|
No |
I |
A |
Maintenance dose: 50 mg mg every 4 weeks/SC |
Etanercept |
Anti-TNF-α |
Induction dose: 50 mg twice a week/SC for 12 weeks |
Moderate to severe plaque psoriasis (>10% PASI, BSA or DLQI) |
Adults: 23% PASI 90 week 122525 Strober B, Thaçi D, Sofen H, Kircik L, Gordon KB, Foley P, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 POETYK PSO-2 trial. J Am Acad Dermatol. 2023;88:29-39.,2626 Xie X, Wang Y, Yao S, Xia Y, Luo H, Li L, et al. Biologics recommendations for patients with psoriasis: a critical appraisal of clinical practice guidelines for psoriasis. J Dermatol Treat. 2022;33:2038-50.
|
Yes |
I |
A |
Maintenance dose: 50 mg once weekly/SC |
JAK-2i |
|
|
|
|
|
|
|
Deucravacitinib |
JAK-2 inh |
6 mg once daily/VO |
Moderate to severe plaque psoriasis (>10% PASI, BSA or DLQI) |
58% PASI 75 week 162525 Strober B, Thaçi D, Sofen H, Kircik L, Gordon KB, Foley P, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 POETYK PSO-2 trial. J Am Acad Dermatol. 2023;88:29-39.,3030 Torres T, Tavares Bello R, Paiva Lopes MJ, Menezes Brandão F, Ferreira A, Ferreira P, et al. Portuguese recommendations for the treatment of psoriasis with biologic therapy. Eur J Dermatol. 2020;30:645-54.
31 Carrascosa JM, Puig L, Belinchón Romero I, Salgado-Boquete L, Del Alcázar E, Andrés Lencina JJ, et al. Practical update of the recommendations published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPS) on the treatment of psoriasis with biologic therapy. Part 1. concepts and general management of psoriasis with biologic therapy. Actas Dermosifiliogr. 2022;113:261-77.-3232 Prignano F, Pescitelli L, Trovato E, DI Cesare A, Cuccia A, Mazzatenta C, et al. Tuscany consensus for the treatment of moderate-severe psoriasis: update and focus on practical guidelines for place in therapy of anti-IL-17 and anti-IL-23 biologics. Ital J Dermatol Venereol. 2022;157:469-79.
|
Yes |
I |
A |